Medicine and Healthcare | Media Room | Newswire

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Fri, 28 Aug 2026 23:00:00 +0000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Lobe Sciences Expands Leadership Team with New CFO Appointment

Fri, 28 Aug 2026 12:00:00 +0000

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Wed, 26 Aug 2026 13:00:00 +0000

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon

Boston Center for Plastic Surgery and Northeast Hair Restoration Welcome Facial Plastic Surgeon Dr. Ashley Lonergan

Tue, 25 Aug 2026 12:00:00 +0000

Dual specialist in facial rejuvenation and hair transplantation brings integrated approach to patients seeking comprehensive results above the shoulders

Vibrant Wellness Brings the Most Comprehensive Gut Health Test to New York

Tue, 25 Aug 2026 04:00:00 +0000

New York State Availability for Gut Zoomer Expands Access to Comprehensive, Multi-Domain Gut Health Testing for Patients With a New York Shipping Address

CMS 2027 Proposed Rule: Key Changes to RPM, RTM and Medicare Care Management

Mon, 24 Aug 2026 19:00:00 +0000

CMS's proposed CY 2027 rule (CMS-1848-P) would reshape RPM and RTM staffing, billing, and eligibility rules. Comment period open through Sept. 14, 2026.

Dr. Dan B. Tran First in Southern California to Implant Clareon(R) TruPlus BLF IOL

Mon, 24 Aug 2026 17:30:00 +0000

Coastal Vision Medical Group Founder Among First Surgeons to Implant Alcon's Newly Launched Clareon TruPlus IOL

Dr. Vinson Eugene Allen Provided Critical Guidance as Actor Ernest Harden Jr. Faced a Medical Emergency While Filming The Pitt

Thu, 20 Aug 2026 22:25:00 +0000

Beloved Actor Ernest Harden Jr. is Grateful, Healthy and Excited to Get Back to Work

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 12:00:00 +0000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Jaguar Health Reports Second Quarter 2026 Financials

Wed, 19 Aug 2026 20:00:00 +0000

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027

REMINDER: Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates (click here to register)

Infinx Builds and Scales Workflow-Integrated AI and Agentic Automation on AWS for Healthcare Revenue Cycle

Wed, 19 Aug 2026 02:05:00 +0000

Infinx expands AWS use to support its Revenue Cycle Agent Platform, enabling workflow-integrated AI, automation, and Document Capture Plus.

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Tue, 18 Aug 2026 13:00:00 +0000

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Tue, 18 Aug 2026 12:30:00 +0000

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 12:00:00 +0000

Imagene AI Joins Proscia Ready Partner Alliance to Advance AI-Powered IHC Companion Diagnostics Development

Tue, 18 Aug 2026 12:00:00 +0000

Integration with Proscia's Concentriq platform will facilitate pharma companies, diagnostic assay and platform providers, and CROs in operationalizing companion diagnostic programs

Vive Concierge Co-Founder Dwayne Hall's Health Equity Work Advances in Sweeping 2026 Senate Bill

Mon, 17 Aug 2026 16:00:00 +0000

Core protections from the Equal Health Care for All Act, which Hall helped conceptualize and advance, are incorporated into the Health Equity and Accountability Act of 2026

Brookside Multicare Nursing Center Earns CMS 5-Star Overall Quality Rating

Thu, 13 Aug 2026 16:30:00 +0000

Brookside Multicare Nursing Center receives the highest overall rating from the Centers for Medicare & Medicaid Services, recognizing excellence in resident care, staffing, and quality measures.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

Thu, 13 Aug 2026 12:15:00 +0000

Toll Brothers Donates $1.6 Million to Help HomeAid Build a Future Without Homelessness

Wed, 12 Aug 2026 14:00:00 +0000

HomeAid is building a future without homelessness

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 12:45:00 +0000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Levita Magnetics Brings MARS(R) Magnetic Surgery Platform to Florida for the First Time

Wed, 12 Aug 2026 10:00:00 +0000

Milestone bariatric procedures at a Miami hospital mark the Florida debut of MARS®, a less invasive approach that reduces incisions, scarring, and recovery time.

Theralogix Expands Its Women's Health Line with Two Breakthrough NSF-Certified Formulas

Wed, 12 Aug 2026 04:00:00 +0000

Introducing Magnesium L-Theanine Complex™ for relaxation and restorative sleep, and TreBiome™, a full-spectrum pre-, pro-, and postbiotic supporting total microbiome balance and both gut and vaginal health.

Paradigm Treatment Receives State Approval to Add Eight Beds at Its Austin Teen Residential Treatment Center

Mon, 10 Aug 2026 13:00:00 +0000

The additional capacity at the Austin, Texas, center responds to sustained demand for adolescent residential mental health care, with the new beds expected to be available in August 2026.

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Mon, 10 Aug 2026 12:30:00 +0000

Holcomb-Kreithen Plastic Surgery & Medspa Named a 2026 Castle Connolly Practice Center of Excellence

Sun, 09 Aug 2026 13:00:00 +0000

White Plains Center for Nursing Care Achieves CMS Overall Five-Star Quality Rating

Wed, 05 Aug 2026 15:00:00 +0000

The prestigious CMS recognition highlights White Plains Center for Nursing Care's commitment to clinical excellence, resident-centered care, and outstanding healthcare outcomes.

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Wed, 05 Aug 2026 13:00:00 +0000

As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi^® and Canalevia^®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications

Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID)

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 12:00:00 +0000

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

ESSE Care Hosts Second Annual Summer Soirée, Celebrating the Partnerships Advancing Endometriosis and Fertility Care

Tue, 04 Aug 2026 11:00:00 +0000

This annual gathering recognizes the physicians, providers, and referral partners who are redefining collaborative patient care.

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

Tue, 28 Jul 2026 13:00:00 +0000

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Tue, 28 Jul 2026 12:30:00 +0000

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Fri, 24 Jul 2026 12:00:00 +0000

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Wed, 22 Jul 2026 13:00:00 +0000

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Wed, 22 Jul 2026 12:30:00 +0000

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

Mon, 20 Jul 2026 13:00:00 +0000

Patent expands intellectual property protection in one of the world's largest cartilage repair markets

GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair

Imagene AI and Tel Aviv Sourasky University Medical Center (Ichilov) Build Clinical AI Infrastructure to Advance Precision Oncology and Biopharma R&D

Thu, 16 Jul 2026 13:00:00 +0000

The collaboration will enable the development, validation, and application of advanced AI technologies to identify clinically meaningful patient subgroups, support biomarker-driven clinical trials, and create a platform for biopharma partnerships advancing innovation and personalized medicine.

New Survey Reveals Wide Gap Between Dentists' and Hygienists' Confidence in Hygiene Appointments

Wed, 15 Jul 2026 21:15:00 +0000

72% of dentists say they're "very confident" hygiene appointments meet best-practice standards; only 29% of hygienists agree, according to a new survey of dental professionals from Alta Voice

How Small and Medium Sized Clinics Can Launch Remote Patient Monitoring

Wed, 15 Jul 2026 19:08:00 +0000

Learn how small and medium-sized clinics can launch a Remote Patient Monitoring (RPM) program with HumHealth to improve patient care and simplify billing.

The Assistance Fund Opens New Program for Hypertriglyceridemia

Wed, 15 Jul 2026 16:00:00 +0000

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Hypertriglyceridemia

Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch

Wed, 15 Jul 2026 13:00:00 +0000

European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production

GelrinC^®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Mon, 13 Jul 2026 13:27:00 +0000

South Beach Detox Meets Rising South Florida Treatment Demand with Individualized Mental Health and Addiction Care

Fri, 10 Jul 2026 13:00:00 +0000

The facility's 36-bed dual-diagnosis program offers a personalized treatment approach in a regional behavioral health system under growing strain

New Survey From The Longevity Centers of America Finds Working-Age Americans More Frustrated With Healthcare Than Seniors

Thu, 09 Jul 2026 14:00:00 +0000

A national survey of 1,750 U.S. adults finds that frustration with the healthcare system runs deepest in midlife, not old age.

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Mon, 22 Jun 2026 13:30:00 +0000

Securitas Healthcare Acquires ZulaFly(TM) to Advance Cloud-Based RTLS and Accelerate Innovation Across Healthcare

Fri, 01 May 2026 12:00:00 +0000

LIV Recovery Center Expands Focus on Dual Diagnosis Treatment

Thu, 29 Jan 2026 16:00:00 +0000

The Georgia rehab center is renewing its commitment to integrated care for individuals with co-occurring mental health and addiction disorders

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Wed, 07 Jan 2026 13:00:00 +0000

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial

AMC Health Announces Breakthrough in AI-Driven Alert Precision for Virtual Care Program

Wed, 07 Jan 2026 11:00:00 +0000

New data science-driven alert framework expected to reduce clinician burden by 45% while preserving industry-leading outcomes, critical amid workforce shortages and rural care challenges

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Tue, 06 Jan 2026 14:00:00 +0000

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure
Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives

Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation

Tue, 06 Jan 2026 13:21:00 +0000

Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint

New peer-reviewed data published in the scientific journal Cartilage uses the complete set of follow-up data from GelrinC's Phase II study, which establishes GelrinC as a leader in long-term durable cartilage repair, using objective, quantitative MOCART assessment to demonstrate morphologic outcomes that consistently outperform other treatment modalities

The data presented by Regentis show that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage, highlighting the long-term durability of GelrinC and reinforcing its competitive superiority in the cartilage repair landscape

GelrinC is already approved in Europe and currently in a pivotal Phase III U.S. FDA study